Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by IMBon Feb 06, 2019 1:06pm

139 Views

Post# 29327040

RE:RE:RE:RE:RE:late in the earning

Jfm1330 I feel you are right last year was early. Has anybody ever thoght that TH has other formulations of egrifta that they have in there war chest? I am sure they are waiting for the data from Dr Grinspoon to release there report. What would be need to by the FDA to advance is to be seen. I feel the only thing that will move this stock is good data JFM1330 has said this in the past and others. WE just need to unfortunately wait. I have always felt that the 3rd drug was something they already had.

Bullboard Posts

Eminent acquires promising Nevada gold project